Blog | BioInformant

Congress Approves Landmark Measure to Reduce Animal Testing

January 28, 2023 By Cade Hildreth, Founder & President Leave a Comment

New methods of testing will involve Organ-on-a-Chip technologies, in vitro testing of stem cell-derived cells and tissues, and in silico models (computer) models.

FDA Modernization Act to spare animals, bring safer and better treatments to patients, and drive down drug prices.

The Future Forecast for MSC-Based Therapeutics

January 27, 2023 By Cade Hildreth, Founder & President Leave a Comment

Presently, MSC-based clinical trials are being conducted for a range of disease conditions, with many completed trials showing safety and efficacy. Clinical utility of MSCs is primarily attributed to their four key biological properties, which include: [Read more…]

BioCentriq Releases Results of Study Designed to Test Transfection of T-cells Using Kytopen’s Flowfect® Technology

January 26, 2023 By Cade Hildreth, Founder & President Leave a Comment

Newark, New Jersey – January 26, 2023 – BioCentriq, Inc.—a New Jersey-based, cell and gene therapy contract development and manufacturing organization (CDMO)—announced today that they’ve completed a study designed to test transfection of T-cells with GFP mRNA for evaluation of cell viability, transfection efficiency, and post transfection growth using Kytopen’s Flowfect® technology. [Read more…]

Athersys Provides MultiStem Clinical Update

January 23, 2023 By Cade Hildreth, Founder & President Leave a Comment

Enrollment completed in second cohort of MATRICS-1 trial in hemorrhagic trauma

Enrollment reaches halfway mark in MASTERS-2 trial in ischemic stroke

CLEVELAND–Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem^® (invimestrocel) for critical care indications, today provided an update on ongoing clinical trials with MultiStem for the treatment of patients following hemorrhagic trauma (MATRICS-1) and for the treatment of ischemic stroke (MASTERS-2). MultiStem is a proprietary off-the-shelf stem cell product in late-stage clinical trials for acute ischemic stroke, as well as trauma and other inflammatory conditions. [Read more…]

CooperSurgical® Announces More than 11,000 Families Have Enrolled in Newborn Possibilities Program®

January 21, 2023 By Cade Hildreth, Founder & President Leave a Comment

Program provides free cord blood and tissue processing to qualifying families in need.

TRUMBULL, Conn., Jan. 5, 2023 — CooperSurgical, a global leader in fertility and women’s health, shared that more than 11,000 families have enrolled in the Newborn Possibilities Program^® through their Cord Blood Registry^® (CBR^®) brand. Through the Newborn Possibilities Program, CBR offers free cord blood and tissue processing and five years of storage for families with a qualifying medical need. [Read more…]